Form 4: Cytosorbents Corp Executive Granted Stock Options Tied to Regulatory Approvals

Efthymios Deliargyris, Chief Medical Officer of Cytosorbents Corp, received stock options contingent on regulatory approvals for DrugSorb-ATR in the US and Canada.

Summary

• Efthymios Deliargyris, the Chief Medical Officer of Cytosorbents Corp, was granted stock options on October 4, 2024.
• The options are divided into two tranches: 100,000 shares contingent on FDA clearance or approval of DrugSorb-ATR, and 50,000 shares contingent on Health Canada clearance or approval of DrugSorb-ATR.
• The exercise price for both sets of options is $1.19.
• The options expire on October 4, 2034.
• Vesting is immediate upon the respective regulatory approvals, provided the approvals are obtained before June 30, 2026, and Deliargyris remains in service.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as it reflects an incentive structure tied to key regulatory milestones, suggesting confidence in the company's ability to achieve these goals. However, the value is contingent on future events.

Positives

• The granting of stock options incentivizes the Chief Medical Officer to pursue regulatory approvals for DrugSorb-ATR.
• The vesting conditions align management's interests with the company's success in achieving regulatory milestones.
• The long expiration date of the options (October 4, 2034) provides a long-term incentive.

Risks

• Failure to obtain FDA or Health Canada approval for DrugSorb-ATR before June 30, 2026, will result in the options not vesting.
• The value of the options is dependent on the future stock price of Cytosorbents Corp, which is subject to market fluctuations.
• The executive leaving the company before the vesting date would result in forfeiture of the options.

Future Outlook

The vesting of the stock options is contingent on future regulatory approvals for DrugSorb-ATR, indicating the company's focus on achieving these milestones.

Industry Context

This announcement reflects a common practice in the biotechnology industry to incentivize key personnel with stock options tied to regulatory and clinical milestones.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry, often used to align management incentives with company performance and regulatory achievements.
• Comparable companies like Aethlon Medical and Spectral Medical also utilize stock options as part of their executive compensation plans, with vesting often tied to clinical trial results or regulatory approvals.
• The size of the grant (150,000 shares) is within the typical range for a Chief Medical Officer at a company of Cytosorbents' size and stage of development.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it incentivizes management to achieve regulatory milestones.
• Employees may be motivated by the potential for company success and the achievement of regulatory approvals.
• The successful approval of DrugSorb-ATR could benefit patients and healthcare providers.

Next Steps

• Cytosorbents will need to achieve FDA and Health Canada approvals for DrugSorb-ATR before June 30, 2026, for the options to vest.
• The reporting person must remain in service for the options to vest.

Key Dates